Ruud De Wildt

Ruud is Vice President of Pipeline at T-Therapeutics. He was previously Global Head of Antibody Lead Discovery at Biopharm GSK, where he led a multidisciplinary team managing all in vitro and in vivo discovery and optimisation processes that delivered >50 antibody projects and therapeutic molecules of which several progressed into clinical studies.

Prior to his 15 years at GSK, Ruud was a founding scientist and associate director at Domantis. He completed his PhD in the Department of Biochemistry at University of Nijmegen, Netherlands.